Bispecific antigen-binding molecules and methods of use

US11866498B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Diego Ellerman · San Francisco, US
• Teemu T. Junttila · San Mateo, US
• Twyla Noelle Lombana · San Francisco, US
• Dionysos Slaga · Richmond, US
• Christoph Spiess · South San Francisco, US

Key dates

• Filing date: Feb 8, 2019
• Grant date: Jan 9, 2024
• Expiry date: Jan 12, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K16/468
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.